Insulet
(Nasdaq: PODD)
announced that it entered into an amended credit agreement to replace existing term loans.
The automated insulin delivery technology developer entered into the agreement with Morgan Stanley Senior Funding. This agreement amended a credit agreement dated May 4, 2021. Pursuant to the agreement, the $487.5 million in term loans outstanding under the existing agreement was replaced with an equal amount of new term loans.
Get the full story at our sister site, Drug Delivery Business News.